2110. Variation in and predictors of vancomycin treatment among patients with Clostridium difficile Infection
Session: Poster Abstract Session: Clostridium difficile: Therapeutics
Saturday, October 29, 2016
Room: Poster Hall
Background: Vancomycin is superior to metronidazole for clinical cure and may result in a reduced risk of mortality among patients with severe Clostridium difficile infection (CDI). Vancomycin utilization among patients with mild to moderate and severe CDI is not well understood. The purpose of this study was to determine how frequently vancomycin is used to treat CDI and to identify characteristics of patients and CDI episodes more likely to receive vancomycin

Methods: We conducted a retrospective cohort study of all patients treated for CDI within the US Department of Veterans Affairs (VA) health care system between January 1, 2005 and December 31, 2012. A diagnosis of CDI was based on a positive laboratory result. Initial treatment was defined as treatment with metronidazole or oral vancomycin during the two days prior to or after the positive CDI test. Changes in rates over time were evaluated using Poisson regression. Vancomycin use was modeled as a function of patient and episode characteristics using logistic regression within a generalized estimating equations framework to account for clustering at the patient and facility levels. Episode severity was measured using the SHEA/IDSA criteria

Results: During the study period, 65,296 patients met the criteria for inclusion in the study. Of these, 9,197 (14.1%) received vancomycin either alone or in combination with metronidazole. The use of vancomycin increased significantly over time from 7.4% of treated episodes in 2005 to 21.9% of treated episodes in 2012 (p<.0001). Using SHEA/IDSA criteria, 52.3%, 37.2%, and 10.5% of episodes were classified as mild to moderate, severe, and unknown severity, respectively. Vancomycin was slightly but significantly more common among patients with severe CDI (15.4% vs. 12.7%, p<.0001). Predictors of vancomycin use included age at diagnosis, prior CDI episodes, hospital onset, severity, recurrent episode, and year

Conclusion: Vancomycin is used as the initial treatment in 15-20% of CDI cases. The use of vancomycin has increased since 2005, but it remains underutilized among patients with severe CDI. Targeted treatment of severe patients with vancomycin could be considered as a means of improving outcomes for patients with CDI

Vanessa W. Stevens, PhD1,2, Karim Khader, PhD1, Richard E. Nelson, PhD1, Damon Toth, PhD3, Molly Leecaster, PhD4, Matthew Samore, MD, FSHEA5 and Michael Rubin, MD, PhD, FIDSA2, (1)Ideas Center, VA Salt Lake City Health Care System, Salt Lake City, UT, (2)Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, (3)Internal Medicine (Epidemiology), University of Utah School of Medicine, Salt Lake City, UT, (4)Salt Lake City VA Health Care System, Salt Lake City, UT, (5)University of Utah School of Medicine, Division of Epidemiology, Salt Lake City, UT

Disclosures:

V. W. Stevens, None

K. Khader, None

R. E. Nelson, None

D. Toth, None

M. Leecaster, None

M. Samore, None

M. Rubin, None

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.